NEW YORK, NY--(Marketwire - Feb 12, 2013) - Health Care stocks have been on an impressive run to start 2013. The Affordable Care Act will provide millions of Americans with access to healthcare, creating new revenue streams for companies across the sector. Research Driven Investing examines investing opportunities in the Health Care Sector and provides equity research on PharMerica Corporation (
Access to the full company reports can be found at:
The Affordable Care Act (Obamacare) requires every American to acquire health insurance by 2014 or be subjected to a tax. For those who can't afford health insurance they will be offered subsidies or Medicaid. Statistics from the Census Bureau show that approximately 50 million Americans did not have health insurance in 2009.
According to the Centers for Medicare and Medicaid Services total health care spending is projected to grow from an estimated $2.8 trillion last year to $4.8 trillion by 2021, an increase of 70 percent. "There's just a lot more money flowing into health care and we're seeing the markets react accordingly," says Invesco portfolio manager, Derek Taner.
Research Driven Investing releases regular market updates on the Health Care Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and industry newsletters.
PharMerica is a leading institutional pharmacy, specialty infusion and hospital pharmacy management services company servicing healthcare facilities in the United States. The company operates pharmacies in 45 states. The company recently reported revenues in the fourth quarter declined 12.6 percent year-over-year to $433.2 million.
Rite Aid is one of the nation's leading drugstore chains with more than 4,600 stores in 31 states and the District of Columbia and fiscal 2012 annual revenues of $26.1 billion. The company swung to a net income of $61.9 million in the third quarter of 2012, compared to a net loss of $52 million in the year ago quarter.
Research Driven Investing has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: